Translational Approaches for Human Liver Disease

Non-alcoholic steatohepatitis (NASH) is the second leading cause of disease driving the need for liver transplantation in the United States with no approved treatments currently available. While a number of clinical approaches are under investigation, historically many promising drug candidates have not demonstrated clinical benefit, in part due to an over-reliance on animal models.
In vitro approaches that incorporate primary human cell types to model disease have the potential to improve clinical success by bridging the gap from preclinical animal models to patients. This symposium will present cutting-edge research highlighting current and emerging in vitro model systems, covering potential benefits and limitations for the treatment of liver disease.